DERM · NASDAQ
Average $14.79 (+183.3% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| B. Riley Securities | Aug 13, 2026 | Maintains | Buy |
| HC Wainwright & Co. | Mar 26, 2026 | Maintains | Buy |
Updated Sep 12, 2026
Journey Medical is a promising commercial-stage pharmaceutical company with a strong focus on the treatment of dermatological conditions. Their FDA-approved prescription drugs and growing sales demonstrate the company's potential for long-term success. Although there may be commercialization risks and potential financing needs, current positive momentum in demand, market access, and high-quality coverage positions the company for continued growth and value creation for investors.
Journey Medical is currently facing several challenges that may affect its financial performance including competitive pressures, slower-than-expected uptake of its product Emrosi, and regulatory and clinical risks with its pipeline candidates. Furthermore, the company's valuation is based on a discounted cash flow model and may be subject to risks such as slower-than-expected revenue growth and potential capital requirements if cash burn exceeds projections. These factors, combined with lower-than-expected revenue and EPS for the latest quarter, could lead to further declines in the company's stock price.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
